rs1402837 — G6PC2 G6PC2 Fasting Glucose Variant

G6PC2: The Pancreatic Glucose Thermostat

Inside every pancreatic beta cell, a molecular tug-of-war determines your fasting blood glucose set point. Glucokinase¹¹ Glucokinase
An enzyme that phosphorylates glucose to glucose-6-phosphate (G6P), initiating glycolysis and triggering insulin release acts as an accelerator, driving glucose into the glycolytic pathway. G6PC2 acts as the brake — it hydrolyzes G6P back into free glucose, creating a futile cycle that raises the glucose concentration required to trigger insulin secretion. The balance between these two enzymes defines the glucose-sensing threshold²² glucose-sensing threshold
The minimum blood glucose concentration that stimulates meaningful insulin release from beta cells — your personal fasting glucose set point.

rs1402837 sits 646 bp upstream of the G6PC2 transcription start site, in a region of open chromatin in human pancreatic islets. It is in very high linkage disequilibrium³³ linkage disequilibrium
LD r²=0.97, meaning the two variants are inherited together 97% of the time and tag the same underlying signal with the lead GWAS variant rs34177044. When the T allele disrupts regulatory element activity at this position, less G6PC2 is expressed in beta cells — the brake eases, glycolytic flux increases at lower glucose concentrations, and the fasting glucose set point shifts downward.

The Mechanism

G6PC2 is expressed almost exclusively in pancreatic islets, where it counteracts glucokinase by converting G6P back to glucose. This substrate futile cycle⁴⁴ futile cycle
A metabolic loop that dissipates energy without net product synthesis; here it makes the beta cell less sensitive to rising glucose raises the glucose level at which insulin secretion is triggered. Research from 2025 also showed that G6PC2 operates in alpha cells, where it defines the glucose concentration at which glucagon secretion is suppressed — linking the locus to both hormonal arms of glucose regulation. ⁵⁵ Bahl et al. 2025 Science Translational Medicine — G6PC2 controls glucagon set point in alpha cells; allele-specific expression confirmed at linked variants

The rs1402837 T allele falls in an open chromatin region detected by H3K4me3 ChIP-seq in human islets, consistent with a cis-regulatory role. It is one of several upstream variants (alongside intronic and promoter variants such as rs560887, rs573225, and rs2232316) that collectively modulate G6PC2 transcript abundance and, consequently, the fasting glucose set point.

The Evidence

The association between the G6PC2 locus and fasting glucose is one of the most strongly replicated signals in human metabolic genetics. rs1402837 specifically was identified in a genome-wide scan of HbA1c⁶⁶ genome-wide scan of HbA1c
Paré et al. 2008 — novel association of HK1 and G6PC2 loci with glycated haemoglobin in 14,618 non-diabetic women; rs1402837 p=6.8×10⁻¹⁰, explaining 0.2% of HbA1c variance in 14,618 apparently healthy Caucasian women. The variant is in very high LD with the fasting glucose lead signal rs34177044, which was replicated in 5,786 non-diabetic Chinese individuals at p=6.9×10⁻¹² (β=0.145 mmol/L per glucose-raising allele) ⁷⁷ Spracklen et al. 2018 PLoS Genetics — functional analysis of glycemic trait loci in the China Health and Nutrition Survey.

The broader G6PC2 locus has been studied in meta-analyses covering up to 187,968 non-diabetic participants, confirming that variants at this locus collectively explain approximately 1–2% of fasting glucose variance — a substantial fraction for common genetic variants. Importantly, the glucose-raising effect is seen without increased type 2 diabetes risk in most populations, consistent with G6PC2's role in setting the fasting setpoint rather than impairing overall glucose tolerance. ⁸⁸ Baerenwald et al. 2013 Diabetologia — multiple functional G6PC2 polymorphisms contribute additively to fasting plasma glucose elevation

The gene is also expressed in alpha cells, where it regulates glucagon suppression threshold. Recent functional studies showed that G6pc2 deletion in alpha cells improves glucose-mediated glucagon suppression, pointing to a bihormonal mechanism and a potential therapeutic target for pharmacological inhibition.

Practical Actions

The T allele at rs1402837 lowers the fasting glucose set point through reduced G6PC2 expression. Carriers benefit from an inherently lower fasting glucose baseline that requires no intervention. For those with the common CC genotype — where both copies of the C reference allele maintain full G6PC2 expression — the glucose set point sits higher. While this is not pathological, it represents a quantifiable contribution to lifetime glycemic load. The most actionable lever for CC carriers is limiting dietary inputs that directly challenge the already-higher fasting glucose threshold: refined carbohydrates and high-glycemic foods raise postprandial glucose spikes that interact with the elevated set point. Spreading carbohydrate intake across smaller, more frequent meals — rather than large boluses — reduces peak beta-cell demand. Regular aerobic activity independently lowers the fasting glucose set point through AMPK-mediated pathways that do not involve G6PC2.

Interactions

The G6PC2 fasting glucose signal is additive with variants in glucokinase (GCK, rs1799884) and the glucokinase regulatory protein gene (GCKR, rs1260326), which operate on the same beta-cell glucose-sensing pathway from the opposite direction. Individuals carrying glucose-raising alleles at both G6PC2 and GCK show compounded effects on fasting glucose and insulin secretion capacity. The combined risk allele score across G6PC2, GCK, GCKR, and MTNR1B variants is associated with meaningful fasting glucose elevation and increased type 2 diabetes risk. ⁹⁹ Li et al. 2009 Diabetes — additive effects of GCK and G6PC2 variants on insulin secretion and fasting glucose (BetaGene + METSIM cohorts)